Information Provided By: 
Fly News Breaks for July 15, 2015
RCPT, CELG
Jul 15, 2015 | 05:52 EDT
Piper Jaffray analyst Joshua Schimmer views the acquisition of Receptos (RCPT) as "another good move" for Celgene (CELG). Schimmer feels Receptos is an attractive asset and believes Celgene continues to plan for life post-Revlimid. He keeps an Overweight rating on Celgene with a $144 price target.
News For CELG;RCPT From the Last 2 Days
There are no results for your query CELG;RCPT
